Literature DB >> 11994053

Pharmacokinetic/pharmacodynamic model for prednisolone inhibition of whole blood lymphocyte proliferation.

Mindy He Magee1, Robert A Blum, Christian D Lates, William J Jusko.   

Abstract

AIMS: Mitogen-induced ex vivo whole blood lymphocyte proliferation (WBLP) is a widely used method to assess lymphocyte responsiveness to immunosuppressive therapy. A three-component complex model was developed to characterize effects of prednisolone on cell trafficking, transduction, and lymphocyte suppression.
METHODS: An oral dose (0.27 mg kg-1) of prednisone was given to 32 subjects. The study consisted of baseline and prednisone phases each with 32 h of sampling. Measurements included plasma prednisolone concentrations, in vitro and ex vivo WBLP, and lymphocyte cell counts during baseline and prednisone phases.
RESULTS: The final model consists of a precursor-dependent indirect response model with a first-order periodic influx rate for lymphocyte trafficking. This accounts for the rebound phenomenon and the circadian rhythm seen in all individual ex vivo WBLP effect-time profiles. Prednisolone was modelled as inhibiting lymphocyte influx from the precursor to the blood pools. The direct suppressive effect of prednisolone on WBLP was modelled with the simple Imax model. A transduction step with rate constant kt was introduced to the simple Imax model to account for the delay ( approximately 4 h) in reaching the maximum inhibition. The IC50 values obtained ex vivo were circa 10 times lower than in vitro values (3.76 vs 38.8 ng ml-1), suggesting additional in vivo factors may have enhanced lymphocyte response to the inhibitory effect of prednisolone.
CONCLUSIONS: This integrated PK/PD model enables evaluation of multicomponent direct and indirect inhibition of ex vivo WBLP by steroids and other immunosuppressants in relation to sex and race.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11994053      PMCID: PMC1874371          DOI: 10.1046/j.1365-2125.2002.01567.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  20 in total

Review 1.  New glucocorticoids. Mechanisms of immunological activity at the cellular level and in the clinical setting.

Authors:  M Scudeletti; L Castagnetta; B Imbimbo; F Puppo; I Pierri; F Indiveri
Journal:  Ann N Y Acad Sci       Date:  1990       Impact factor: 5.691

2.  Evaluation of dose-related pharmacokinetics and pharmacodynamics of prednisolone in man.

Authors:  J A Wald; R M Law; E A Ludwig; R R Sloan; E Middleton; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1992-12

3.  Pharmacodynamic model for joint exogenous and endogenous corticosteroid suppression of lymphocyte trafficking.

Authors:  M A Milad; E A Ludwig; S Anné; E Middleton; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1994-12

4.  Fifteen years of operation of a high-performance liquid chromatographic assay for prednisolone, cortisol and prednisone in plasma.

Authors:  W J Jusko; N A Pyszczynski; M S Bushway; R D'Ambrosio; S M Mis
Journal:  J Chromatogr B Biomed Appl       Date:  1994-08-05

5.  Circadian changes of T lymphocyte subsets in human peripheral blood.

Authors:  T Miyawaki; K Taga; T Nagaoki; H Seki; Y Suzuki; N Taniguchi
Journal:  Clin Exp Immunol       Date:  1984-03       Impact factor: 4.330

Review 6.  Immunopharmacologic therapy in renal transplantation.

Authors:  A S Shoker
Journal:  Pharmacotherapy       Date:  1996 Jul-Aug       Impact factor: 4.705

7.  Novel mechanism for inhibition of human T cells by glucocorticoids. Glucocorticoids inhibit signal transduction through IL-2 receptor.

Authors:  F Paliogianni; S S Ahuja; J P Balow; J E Balow; D T Boumpas
Journal:  J Immunol       Date:  1993-10-15       Impact factor: 5.422

8.  Gender-based effects on methylprednisolone pharmacokinetics and pharmacodynamics.

Authors:  K H Lew; E A Ludwig; M A Milad; K Donovan; E Middleton; J J Ferry; W J Jusko
Journal:  Clin Pharmacol Ther       Date:  1993-10       Impact factor: 6.875

Review 9.  Molecular mechanisms of new immunosuppressants.

Authors:  P F Halloran
Journal:  Clin Transplant       Date:  1996-02       Impact factor: 2.863

10.  Prednisolone disposition in obese men.

Authors:  R L Milsap; K I Plaisance; W J Jusko
Journal:  Clin Pharmacol Ther       Date:  1984-12       Impact factor: 6.875

View more
  18 in total

1.  Optimal designs for composed models in pharmacokinetic-pharmacodynamic experiments.

Authors:  Holger Dette; Andrey Pepelyshev; Weng Kee Wong
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-05-22       Impact factor: 2.745

Review 2.  Pharmacokinetic/pharmacodynamic modeling in inflammation.

Authors:  Hoi-Kei Lon; Dongyang Liu; William J Jusko
Journal:  Crit Rev Biomed Eng       Date:  2012

3.  T-cell numbers and antigen-specific T-cell function follow different circadian rhythms.

Authors:  Sarah Kirsch; Stephan Thijssen; Susana Alarcon Salvador; Gunnar H Heine; Kai van Bentum; Danilo Fliser; Martina Sester; Urban Sester
Journal:  J Clin Immunol       Date:  2012-07-15       Impact factor: 8.317

4.  MDR-1 gene polymorphisms and clinical course of steroid-responsive nephrotic syndrome in children.

Authors:  Anna Wasilewska; Grzegorz Zalewski; Lech Chyczewski; Walentyna Zoch-Zwierz
Journal:  Pediatr Nephrol       Date:  2006-10-17       Impact factor: 3.714

Review 5.  Transitioning from Basic toward Systems Pharmacodynamic Models: Lessons from Corticosteroids.

Authors:  Vivaswath S Ayyar; William J Jusko
Journal:  Pharmacol Rev       Date:  2020-04       Impact factor: 25.468

Review 6.  Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids.

Authors:  David Czock; Frieder Keller; Franz Maximilian Rasche; Ulla Häussler
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

Review 7.  The role of glucocorticoids and progestins in inflammatory, autoimmune, and infectious disease.

Authors:  A Sasha Tait; Cherie L Butts; Esther M Sternberg
Journal:  J Leukoc Biol       Date:  2008-07-29       Impact factor: 4.962

8.  Sudden sensorineural hearing loss: systemic steroid therapy and the risk of glucocorticoid-induced hyperglycemia.

Authors:  Christian Rohrmeier; Nikola Koemm; Philipp Babilas; Philipp Prahs; Juergen Strutz; Roland Buettner
Journal:  Eur Arch Otorhinolaryngol       Date:  2012-07-28       Impact factor: 2.503

9.  Assessment of the impact of dosing time on the pharmacokinetics/pharmacodynamics of prednisolone.

Authors:  Jian Xu; Julia Winkler; Sreedharan Nair Sabarinath; Hartmut Derendorf
Journal:  AAPS J       Date:  2008-06-25       Impact factor: 4.009

10.  Pharmacokinetic/pharmacodynamic models for the depletion of Vbeta5.2/5.3 T cells by the monoclonal antibody ATM-027 in patients with multiple sclerosis, as measured by FACS.

Authors:  Per-Henrik Zingmark; Charlotte Edenius; Mats O Karlsson
Journal:  Br J Clin Pharmacol       Date:  2004-10       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.